- Becton Dickinson raised its full-year adjusted earnings per share (EPS) forecast to a range of $14.30 to $14.45, which is an increase from the previous range of $14.06 to $14.34.
- The company now expects GAAP revenue growth between 8.2% and 8.7%, an increase from the prior estimate of 8% to 8.5%.
- Organic revenue growth expectations remain unchanged at 3% to 3.5%, with an estimate of 3.2%.
- For the third quarter, Becton Dickinson reported adjusted EPS of $3.68, surpassing the estimate of $3.40.
- Third-quarter revenue reached $5.51 billion, slightly above the estimated $5.49 billion.
- The Medical segment’s revenue was $2.93 billion, while Medication Delivery Solutions came in at $1.13 billion, just shy of expectations.
- Medication Management Solutions earned $888 million, exceeding estimates of $867.9 million.
- Pharmaceutical Systems achieved $629 million in revenue, higher than the estimated $612.2 million.
- Life sciences revenues were $1.25 billion, slightly under the $1.27 billion estimate.
- Biosciences made $358 million, aligning closely with the $357.4 million expectation.
- Interventional segment revenue totaled $1.33 billion, ahead of the projected $1.32 billion.
- Surgery generated $395 million in revenue, which was slightly lower than the $398.7 million estimate.
- Peripheral Intervention revenue was $512 million, just under the estimated $514.2 million.
- Urology and Critical Care revenue was notably higher at $422 million, compared to the estimate of $403.5 million.
- The company mentions an anticipated neutral effect on adjusted EPS from translational foreign currency changes but a $10 million increase in revenue year over year.
“`
Becton Dickinson and Co on Smartkarma
Analyst coverage of Becton Dickinson and Co on Smartkarma, as highlighted by Baptista Research, delves into the company’s recent first quarter fiscal 2025 earnings presentation. The analysis applauds BD for its strong financial performance and strategic decisions that may shape its future. Key updates include remarkable results from current business units, plans to split the Biosciences and Diagnostic Solutions segment, and market potential fueled by continuous innovation. Baptista Research aims to assess various influencing factors on the company’s stock price and conducts an autonomous valuation using a Discounted Cash Flow (DCF) approach.
A look at Becton Dickinson and Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have provided an overall outlook Smart Score for Becton Dickinson and Co, with an average across key factors. The scores indicate that the company holds a solid position in terms of value, dividend, growth, resilience, and momentum. With a balanced score of 3 across most factors, Becton Dickinson and Co seems to be positioned for steady performance in the long run.
Becton, Dickinson and Company, a global medical technology firm, specializes in the development and sale of medical devices, instrument systems, and reagents. Engaged in serving various sectors including healthcare institutions, life science researchers, clinical laboratories, and pharmaceutical industry, the company maintains a diversified portfolio. The ratings across different factors suggest a stable outlook for Becton Dickinson and Co in the foreseeable future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
